(6aR,9R)-N-cyclohexyl-9-(pyrrolidine-1-carbonyl)-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-7(4H)-carboxamide

ID: ALA1809028

Chembl Id: CHEMBL1809028

PubChem CID: 56673942

Max Phase: Preclinical

Molecular Formula: C26H32N4O2

Molecular Weight: 432.57

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C([C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)NC2CCCCC2)C1)N1CCCC1

Standard InChI:  InChI=1S/C26H32N4O2/c31-25(29-11-4-5-12-29)18-13-21-20-9-6-10-22-24(20)17(15-27-22)14-23(21)30(16-18)26(32)28-19-7-2-1-3-8-19/h6,9-10,13,15,18-19,23,27H,1-5,7-8,11-12,14,16H2,(H,28,32)/t18-,23-/m1/s1

Standard InChI Key:  LPYNOOBUNPCVBY-WZONZLPQSA-N

Associated Targets(Human)

CXCR3 Tchem C-X-C chemokine receptor type 3 (2736 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Cxcr3 C-X-C chemokine receptor type 3 (96 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 432.57Molecular Weight (Monoisotopic): 432.2525AlogP: 4.07#Rotatable Bonds: 2
Polar Surface Area: 68.44Molecular Species: NEUTRALHBA: 2HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: 2.89CX LogD: 2.89
Aromatic Rings: 2Heavy Atoms: 32QED Weighted: 0.75Np Likeness Score: -0.08

References

1. Thoma G, Baenteli R, Lewis I, Jones D, Kovarik J, Streiff MB, Zerwes HG..  (2011)  Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood.,  21  (16): [PMID:21764306] [10.1016/j.bmcl.2011.06.070]

Source